
    
      The primary objective of this study is to assess the efficacy of rifaximin SSD plus lactulose
      versus placebo plus lactulose for the treatment of overt hepatic encephalopathy (OHE). The
      secondary objectives of this study are to assess the safety of rifaximin SSD in subjects with
      OHE and to assess the effects of treatment with rifaximin SSD on key secondary endpoints.
    
  